Clinical trials: Patients with Multiple Sclerosis
Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study
This study is a national, prospective, multicenter, non-interventional (observational) study with the aim to describe the impact of Siponimod treatment in a real-world SPMS population in Switzerland who are treated with Siponimod…
- Trial name
- SWISSMASIA (NCT04895202)
- Testing
- Siponimod
- Where
- 6 sites in Switzerland
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Cognitive Change
EMRESERVA to Enhance Cognitive Reserve in Multiple Sclerosis
Multiple Sclerosis(MS) is an immunological degenerative disease that affects central nervous system causing cognitive impairment, which is one of the most disabling symptoms in MS.
- Trial name
- NCT05546424
- Testing
- EMRESERVA
- Where
- Spain
- Volunteers
- 58 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine [23-PPV] either unboosted or boosted…
- Trial name
- NCT02545868
- Testing
- 23-PPV, 13-PCV Booster, Influenza Vaccine
- Where
- 22 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Rehabilitative Protocols in Progressive Multiple Sclerosis Treated with Anti CD20 Monoclonal Antibodies
Progressive multiple sclerosis (MS) patients have usually a worsening clinical course and it remains unclear if rehabilitation can indeed slow down the progression of the disease.
- Trial name
- Reup (NCT06894940)
- Testing
- Active Comparator #1, Experimental
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- University of Pavia
Secondary Progressive Multiple Sclerosis
Study Evaluating Mitoxantrone in Multiple Sclerosis
The purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in patients with secondary progressive multiple sclerosis and to show the safety and tolerability of…
- Trial name
- NCT00146159
- Testing
- Mitoxantrone
- Where
- 7 sites in Germany
- Volunteers
- 336 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Primary Progressive Multiple Sclerosis
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.
- Trial name
- ORATORIO-Cort (NCT05974839)
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 732 people
- Sponsor
- State University of New York at Buffalo
Multiple Sclerosis, Relapsing-Remitting
An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
The present study aims to assess the adherence to therapy with interferon beta-1a (Rebif®) and at investigating potential factors that are involved in its outcome, in a representative sample of patients with relapsing remitting…
- Trial name
- NCT01112345
- Where
- Greece
- Volunteers
- 133 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Sarcopenia
Investigation of the Prevalence of Sarcopenia and Dynapenia According to Disease Stage in Patients With Multiple Sclerosis and Evaluation of the Relationship Between Sarcopenia Severity and Clinical and Functional Parameters
This cross-sectional observational study aims to determine the prevalence of sarcopenia and dynapenia across disability stages in patients with multiple sclerosis (MS) and investigate their associations with clinical and…
- Conditions
- Multiple Sclerosis, Sarcopenia, Dynapenia
- Trial name
- MS-Sarcopenia (NCT07842731)
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Atılım University
Multiple Sclerosis
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in patients with multiple sclerosis.
- Trial name
- NCT01764737
- Testing
- VX15/2503
- Where
- 10 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vaccinex Inc.
Multiple Sclerosis
Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate
Rates of brain atrophy for long term users of fingolimod when compared to glatiramer acetate have not been examined in patients with relapsing forms of multiple sclerosis (MS).
- Trial name
- NCT02307877
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis, Relapsing-Remitting
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon…
- Trial name
- CARE-MS II (NCT00548405)
- Testing
- Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a
- Where
- 191 sites in United States, Argentina and 21 more
- Volunteers
- 840 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis, Gait Disorders, Neurologic
"Balance, Gait, and Motion Analysis in Multiple Sclerosis"
The goal of this observational cross-sectional study is to investigate the relationship between functional measures of balance and gait and objective kinetic and kinematic parameters in people with Multiple Sclerosis (MS).
- Conditions
- Multiple Sclerosis, Gait Disorders, Neurologic, Postural Balance, Motion Analysis
- Trial name
- MS-BALGAIT (NCT07630311)
- Where
- 2 sites in Greece
- Volunteers
- 40 people
- Sponsor
- University of Patras
Relapsing Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
This study aimed to understand whether patients with relapsing multiple sclerosis (RMS) can mount an immune response to SARS-CoV-2 mRNA vaccines (initial vaccinations or booster vaccines) when vaccinated either before initiation…
- Trial name
- KYRIOS (NCT04869358)
- Testing
- Ofatumumab
- Where
- 6 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who have had a suboptimal…
- Trial name
- NCT02861014
- Testing
- Ocrelizumab
- Where
- 163 sites in Australia, Belgium and 15 more
- Volunteers
- 681 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Cognitive Impairment
MODAFIMS: A Trial to Evaluate Predictors of Response to MODAFinil in Patients With Multiple Sclerosis
This is a phase II/exploratory clinical trial with a single-center, open-label design to evaluate the effect of modafinil on cognitive deficits in adult patients with multiple sclerosis and identify predictors of response using…
- Trial name
- MODAFIMS (NCT06592352)
- Testing
- Modafinil Generis 100 mg
- Where
- Portugal
- Volunteers
- 64 people
- Sponsor
- Clinical Academic Center (2CA-Braga)
Multiple Sclerosis
Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment
Information from blood samples may help us for choosing the best treatment in future personalized medicine. Natalizumab (NTZ) a current treatment for MS can be used as a second line therapy if a suboptimal response to disease…
- Trial name
- Bionat2 (NCT00942214)
- Testing
- Natalizumab
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Toulouse
Multiple Sclerosis
French Adaptation of the California Card Sorting Task (CCST) in Multiple Sclerosis
Cognitive impairment affects up to 65% of multiple sclerosis (MS) subjects, especially executive functions. The California Card Sorting Task (CCST) assesses specific components of problem-solving ability.
- Trial name
- E3C-DIFSEP (NCT02887352)
- Testing
- assessment of problem-solving ability
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Multiple Sclerosis, Relapsing-Remitting, Vitamin D Deficiency
Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis
Vitamin D is important risk factor for developing multiple sclerosis (MS) and for disease progression. Patients with MS who had lower vitamin D levels were at increased risk for more clinical attacks and faster disease…
- Trial name
- NCT03385356
- Testing
- Vitamin D
- Where
- Slovenia
- Volunteers
- 89 people
- Sponsor
- University Medical Centre Maribor
Multiple Sclerosis, Diet Therapy
Investigation of the Effect of the MIND Diet on Disease Symptoms in Patients With MS
The planned parallel group, randomized controlled study design will be used to determine the effects of the MIND diet applied to MS patients on fatigue, quality of life, technological function and brain fog and to contribute to…
- Conditions
- Multiple Sclerosis, Diet Therapy, Body Composition, Randomised Controlled Trial
- Trial name
- MS (NCT07057999)
- Testing
- MIND Diet (Mediterranean-DASH Intervention for Neurodegenerative Delay), Traditional healthy nutrition program specific to Turkey
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people
- Sponsor
- Betul Uner
Multiple Sclerosis
Cognitive Improvement Through tDCS for Patients With Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease with around 200.000 patients in Germany. Besides physical symptoms, cognitive resources degrade over the years.
- Trial name
- MS-CICS (NCT04667221)
- Testing
- Active transcranial direct current stimulation
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Medicine Greifswald